Jing Ma, Wei Zhang, Hui-Fu Wang, Zi-Xuan Wang, Teng Jiang, Meng-Shan Tan, Jin-Tai Yu1, Lan Tan2. 1. Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao, Shandong Province 266071, China. yu-jintai@163.com. 2. Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao, Shandong Province 266071, China. dr.tanlan@163.com.
Abstract
BACKGROUND: Although peripheral blood adipokines and insulin levels have been considered to be biomarkers of Alzheimer's disease (AD), previous researches about levels of adipokines and insulin in blood are no conclusive. We designed this meta-analysis to validate whether peripheral adipokines and insulin can be used as a candidate biomarker in AD diagnosis. METHODS: We carried out a replication study in serum by ourselves and further conducted a meta-analysis to estimate the different levels of peripheral blood adipokines and insulin between AD patients and controls. In the section of meta-analysis, the pooled weighted mean difference (WMD) and 95% confidence interval (CI) was used to compare the levels of adipokines and insulin in different groups. RESULTS: According to our replication study, there is statistically significant lower in the levels of leptin, but conspicuous higher in the levels of adiponectin and insulin in the blood of AD patients than controls. We finally identified four studies for leptin, four studies for adiponectin and eleven studies for insulin. From the random-effect model, the pooled WMD of the levels of leptin, adiponectin and insulin of AD subjects compared with the controls was -3.90 ng/ml (95% CI: [-5.68, -2.13]), 9.42 µg/mL (95% CI: [4.21, 14.62]), and 2.86 µIU/ml (95% CI: [1.21, 4.50]), respectively. CONCLUSION: Our replication study and meta-analysis support lower levels of leptin and higher levels of adiponectin and insulin in AD patients with respect to controls, and indicate their potential values as important risk factors for AD. Further researches that using standardized assay for leptin, adiponectin, and insulin measurement are still needed to reveal the potential change of peripheral blood leptin, adiponectin, and insulin levels in AD participants.
BACKGROUND: Although peripheral blood adipokines and insulin levels have been considered to be biomarkers of Alzheimer's disease (AD), previous researches about levels of adipokines and insulin in blood are no conclusive. We designed this meta-analysis to validate whether peripheral adipokines and insulin can be used as a candidate biomarker in AD diagnosis. METHODS: We carried out a replication study in serum by ourselves and further conducted a meta-analysis to estimate the different levels of peripheral blood adipokines and insulin between ADpatients and controls. In the section of meta-analysis, the pooled weighted mean difference (WMD) and 95% confidence interval (CI) was used to compare the levels of adipokines and insulin in different groups. RESULTS: According to our replication study, there is statistically significant lower in the levels of leptin, but conspicuous higher in the levels of adiponectin and insulin in the blood of ADpatients than controls. We finally identified four studies for leptin, four studies for adiponectin and eleven studies for insulin. From the random-effect model, the pooled WMD of the levels of leptin, adiponectin and insulin of AD subjects compared with the controls was -3.90 ng/ml (95% CI: [-5.68, -2.13]), 9.42 µg/mL (95% CI: [4.21, 14.62]), and 2.86 µIU/ml (95% CI: [1.21, 4.50]), respectively. CONCLUSION: Our replication study and meta-analysis support lower levels of leptin and higher levels of adiponectin and insulin in ADpatients with respect to controls, and indicate their potential values as important risk factors for AD. Further researches that using standardized assay for leptin, adiponectin, and insulin measurement are still needed to reveal the potential change of peripheral blood leptin, adiponectin, and insulin levels in ADparticipants.
Authors: Molly Stanley; Shannon L Macauley; Emily E Caesar; Lauren J Koscal; Will Moritz; Grace O Robinson; Joseph Roh; Jennifer Keyser; Hong Jiang; David M Holtzman Journal: J Neurosci Date: 2016-11-16 Impact factor: 6.167
Authors: M Vaňková; G Vacínová; J Včelák; D Vejražková; P Lukášová; R Rusina; I Holmerová; E Jarolímová; H Vaňková; B Bendlová Journal: Physiol Res Date: 2020-09-30 Impact factor: 1.881
Authors: Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow Journal: Nat Rev Drug Discov Date: 2020-07-24 Impact factor: 84.694
Authors: Zoltán P Várhelyi; János Kálmán; Zita Oláh; Eszter V Ivitz; Eszter K Fodor; Miklós Sántha; Zsolt L Datki; Magdolna Pákáski Journal: Front Neurosci Date: 2017-04-11 Impact factor: 4.677
Authors: Antonio J López-Gambero; Cristina Rosell-Valle; Dina Medina-Vera; Juan Antonio Navarro; Antonio Vargas; Patricia Rivera; Carlos Sanjuan; Fernando Rodríguez de Fonseca; Juan Suárez Journal: Int J Mol Sci Date: 2021-05-20 Impact factor: 5.923